ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 475
- Registration Number
- NCT04195698
- Locations
- 🇺🇸
Duplicate_First OC Dermatology Research Inc /ID# 218619, Fountain Valley, California, United States
🇺🇸Duplicate_UC Davis Health /ID# 218582, Sacramento, California, United States
🇺🇸Duplicate_Michigan Center for Research Company /ID# 218577, Clarkston, Michigan, United States
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
- Conditions
- Hepatitis C Virus (HCV)
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 99
- Registration Number
- NCT04189627
- Locations
- 🇷🇺
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 222252, Irkutsk, Russian Federation
🇷🇺Children's Clinical Multidisciplinary Center of the Moscow Region /ID# 226590, Moscow, Russian Federation
🇷🇺Dagestan State Medical University /ID# 218500, Makhachkala, Dagestan, Respublika, Russian Federation
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
- Conditions
- CancerNon-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 65
- Registration Number
- NCT04189614
- Locations
- 🇺🇸
The Ohio State University /ID# 211088, Columbus, Ohio, United States
🇺🇸Stanford University School of Med /ID# 213450, Stanford, California, United States
🇪🇸Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid, Spain
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT04178902
- Locations
- 🇦🇺
Royal Adelaide Hospital /ID# 223354, Adelaide, South Australia, Australia
🇦🇺Royal Perth Hospital /ID# 225498, Perth, Western Australia, Australia
🇦🇺Perth Blood Institute Ltd /ID# 226650, Nedlands, Western Australia, Australia
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
- Conditions
- Cancer, Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT04178317
- Locations
- 🇰🇷
Inje University - Busan Paik Hospital /ID# 233882, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Pusan National University Hospital /ID# 216850, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 233884, 중구, Daegu Gwang Yeogsi, Korea, Republic of
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 734
- Registration Number
- NCT04169373
- Locations
- 🇺🇸
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055, Skokie, Illinois, United States
🇺🇸Arthritis & Rheumatic Disease Specialties /ID# 215306, Aventura, Florida, United States
🇨🇦Toronto Western Hospital /ID# 215041, Toronto, Ontario, Canada
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
- Conditions
- Irritable Bowel Syndrome With ConstipationFunctional Constipation
- Interventions
- Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 389
- Registration Number
- NCT04166058
- Locations
- 🇺🇸
River Birch Research Alliance /ID# 237963, Blue Ridge, Georgia, United States
🇺🇸Advanced Research Center /ID# 237960, Anaheim, California, United States
🇺🇸Dolphin Medical Research /ID# 234676, Doral, Florida, United States
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
- Conditions
- Takayasu Arteritis (TAK)
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 56
- Registration Number
- NCT04161898
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 241175, Sao Paulo, Brazil
🇯🇵Institute of Science Tokyo Hospital /ID# 214138, Bunkyo-ku, Tokyo, Japan
🇰🇷The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214566, Seoul, Seoul Teugbyeolsi, Korea, Republic of
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Cancer
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 465
- Registration Number
- NCT04161885
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia /ID# 215106, Valencia, Spain
🇪🇸Hospital Universitario Virgen del Rocio /ID# 215463, Sevilla, Spain
🇺🇸Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711, Scottsdale, Arizona, United States
Expanded Access to Upadacitinib
- Conditions
- Crohn Disease
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04159597